Navigation Links
Escalon(R) Reports Fourth Quarter and Fiscal 2009 Results
Date:10/13/2009

does not take into account future growth opportunities, expansion efforts presence in the ophthalmology market, or the delay in the development of Sonomed's proposed new instruments. For a more complete discussion of this accounting rule and the results of the impairment test, please refer to the Company's Form 10-K filed on October 13, 2009 with the Securities and Exchange Commission.

For fiscal 2009, cost of goods sold totaled approximately $19,548,000, or 56.7% of product revenues, compared with $17,310,000, or 57.7% of product revenue, for fiscal year 2008. Operating expenses decreased approximately .7% during the fiscal year ended June 30, 2009 as compared to the prior fiscal year. This was due to increased marketing, general and administrative expenses of 3.2% offset by a 14.4% decrease in research and development expenses related to the decision to drastically reduce Drew's research and development department in June 2008 in favor to a move to an outsourced research and development model.

2008 Fourth Quarter Results

For the fourth quarter of fiscal 2009, product revenue increased 2.0% to $8,564,000, compared with $7,566,000 reported in the same period last fiscal year. Product revenues were driven by increased sales related to the acquisition of JAS Diagnostics and Biocode Hycel, offset by decreases at its Sonomed unit.

For the fourth quarter of fiscal 2009, the Company reported a net loss of $(11,104,000), or $(1.55) per diluted share, which includes the goodwill impairment of $9,526,000, compared with net loss of $(11,649,000), or $(1.82) per diluted share, in the fourth quarter of fiscal 2008.

Recap of 2008

Richard J. DePiano, Chairman and Chief Executive Officer, commented, "We continue to produce solid revenue growth through fiscal 2009 and, despite increasing operating expenses, lowered our net loss compared to last fiscal year. While the resulting loss is still disa
'/>"/>

SOURCE Escalon Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Escalon(R) Announces Going Concern Qualification
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... options and research directions , , WASHINGTON, June ... therapeutic option for many patients with interstitial cystitis (IC). IC ... 8 million women and 1.5 million men in the United ... noticed a correlation between allergies and IC. Recently, a urologist ...
... Families of Spinal Muscular Atrophy has just released details ... funded therapeutic pipeline. , , Families of SMA ... Quinazolines to boost gene expression; 2) Tetracyclines at Paratek ... replacement program at California Stem Cell and UCI. ...
Cached Medicine Technology:Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 2Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 3Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 4Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 2Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 3
(Date:7/31/2014)... Mountain View, Calif. and Las Vegas, Nevada (PRWEB) July ... a partnership with LaunchKey to provide next generation authentication ... a simple and secure way to utilize hardware protected ... an enormous problem in the Internet's reliance on password-based ... of hacks and global data breaches taking place around ...
(Date:7/31/2014)... 2014 The Beryl Institute announces three ... and four new members of its Patient ... the global community of practice and premier thought leader ... Executive board members are industry leaders who advise on ... insight into market and industry trends. The advisory board ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... HealthDay Reporter , WEDNESDAY, July 30, ... isn,t warranted based on current evidence, a team of ... compete with regular cigarettes might cut tobacco-related deaths and ... on the use and safety of the nicotine-emitting devices. ... a potential for smokers to reduce their health risks ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... company has launched a new online reputation management ... help individuals as well as organizations get rid ... service is the result of extensive research. ReputationChief.Com ... design a service for those who are struggling ...
Breaking Medicine News(10 mins):Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 2Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2
... , MONDAY, April 11 (HealthDay News) -- Progressive resistance ... to function better in daily life, researchers say. A ... review of available evidence and concluded that an adult can ... and increase their overall strength by 25 percent to 30 ...
... Ore. An Oregon Health & Science University researcher has ... prevent rejection in organ transplant patients helped treat a rare ... cure and, until now, no known treatment. The clinical ... first randomized, controlled study designed to develop a therapy for ...
... By Steven Reinberg HealthDay Reporter , MONDAY, April ... engines cuts emissions of heart-harmful microscopic particles by 98 percent, ... new study suggests. The very tiny particles found in ... heart disease caused by air pollution, but "if we use ...
... treatment for osteoporosis has often been associated with serious ... Sweden, have now, in mice, found a way of ... that only the skeleton is acted on, current research ... in the respected journal PNAS (Proceedings of the National ...
... A study appearing in the journal Investigational New Drugs ... that two new small molecule inhibitors are showing promise ... common malignant bone tumor, osteosarcoma. These small molecule inhibitors ... spice may serve as a new, non-toxic treatment ...
... Nearly all patients with advanced cancer experience severe pain, and ... regardless of the type or stage of the disease. Pain ... new study, led by Wayne State University,s College of Nursing ... Cancer Institute of the National Institutes of Health, aims to ...
Cached Medicine News:Health News:Progressive Weight Training Can Boost Seniors' Strength 2Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 3Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2Health News:Wayne State leads study to improve management of cancer pain in African Americans 2
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE® ESR...
Medicine Products: